Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

BACKGROUND: Immune checkpoint inhibitor-based combinations have expanded the treatment options for patients with renal cell carcinoma (RCC); however, tolerability remains challenging. The aim of this study was to evaluate the safety and efficacy of the immunostimulatory interleukin-2 cytokine prodru...

Descripción completa

Detalles Bibliográficos
Autores principales: Tannir, Nizar M, Cho, Daniel C, Diab, Adi, Sznol, Mario, Bilen, Mehmet A, Balar, Arjun V, Grignani, Giovanni, Puente, Erika, Tang, Lily, Chien, David, Hoch, Ute, Choudhury, Arkopal, Yu, Danni, Currie, Sue L, Tagliaferri, Mary A, Zalevsky, Jonathan, Siefker-Radtke, Arlene O, Hurwitz, Michael E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021810/
https://www.ncbi.nlm.nih.gov/pubmed/35444058
http://dx.doi.org/10.1136/jitc-2021-004419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021810/
https://www.ncbi.nlm.nih.gov/pubmed/35444058
http://dx.doi.org/10.1136/jitc-2021-004419

Ejemplares similares